Freedman Financial Associates, Inc. Zynerba Pharmaceuticals, Inc. Transaction History

Freedman Financial Associates, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.86 - $2.06 $258 - $618	-300 Closed	0 $0
Q2 2021 Jul 13, 2021	SELL	$3.83 - $5.98 $2,298 - $3,588	-600 Reduced 66.67%	300 $2,000
Q4 2020 Feb 17, 2021	BUY	$3.27 - $4.64 $2,943 - $4,176	900 New	900 $3,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Freedman Financial Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Freedman Financial Associates, Inc. with notifications on news.